Taceedo 20mg Injection (Docetaxel)

Taceedo 20mg Injection is a chemotherapy-based anticancer drug. The doctor prescribes it to treat a variety of cancers, such as breast cancer, non-small cell lung cancer, prostate cancer, and head and neck cancer. It contains docetaxel that works by interfering with the microtubule structures to slow the cancer cell multiplication and spread.

This injection should be administered by a healthcare professional only. It can be used alone or in combination with other medication.

Breast Cancer

Like other anticancer medicines, Taceedo 20mg Injection (docetaxel 20mg) also has some common- to-severe-side effects. These undesired symptoms are observed in the body after taking this injection and usually disappear with time as the body adjusts to the medicine. 

However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.​

Common Side Effects Include:
● Low blood platelets
● Hair loss
● Nerve damage
● Neuropathy
● Numbness of extremity
● Taste change
● Breathlessness
● Constipation
● Edema (swelling)
● Infection
● Loss of appetite
● Muscle pain
● Nail disorder
● Pain
● Weakness

Taceedo 20mg Injection (Docetaxel 20mg) is a powerful anticancer medicine that can only be given intravenously by a doctor or nurse under strict medical supervision. It is not self-administerable. Dosage and duration of the treatment are determined by the doctor as per the patient's health condition and type & stage of the cancer.

Taking this injection in the wrong way may give you severe side effects. In case of overdose, contact your healthcare provider or doctor, and they will provide you with medical attention.

● Bissery, M. C., Nohynek, G., Sanderink, G. J., & Lavelie, F. (1995). Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part I: preclinical experience. Anti-cancer drugs, 6(3), 339-355.
● De Souza, R., Zahedi, P., Moriyama, E. H., Allen, C. J., Wilson, B. C., & Piquette-Miller, M. (2010). Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer. Molecular cancer therapeutics, 9(6), 1820-1830.
● Yan, M., Wang, J., Ren, Y., Li, L., He, W., Zhang, Y., ... & Li, Z. (2019). Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization. Cell death & disease, 10(3), 204.
● Gruden, S., Sandelin, M., Rasanen, V., Micke, P., Hedeland, M., Axen, N., & Jeansson, M. (2017). Antitumoral effect and reduced systemic toxicity in mice after intra-tumoral injection of an in vivo solidifying calcium sulfate formulation with docetaxel. European journal of pharmaceutics and biopharmaceutics, 114, 186-193.
● To, H., Shin, M., Tabuchi, M., Sakaguchi, H., Takeuchi, A., Matsunaga, N., ... & Ohdo, S. (2004). Influence of dosing schedule on toxicity and antitumor effects of a combination of adriamycin and docetaxel in mice. Clinical cancer research, 10(2), 762-769.